Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2022-10-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
拟续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Ernst & Young Hua Ming) as the company's auditor for the 2022 fiscal year. It details the auditor's background, qualifications, independence, and the approval process by the audit committee, independent directors, and the board of directors. The document does not contain any financial statements or audit reports themselves but rather the company's announcement about the auditor appointment process and related approvals. The document length is 2760 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about auditor reappointment and does not contain the audit report or financial data itself.
2022-10-19 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 嘉事堂药业股份有限公司, detailing the decisions made at the sixth board's twentieth meeting. It includes approval of the 2022 third quarter report, election of an independent director, reappointment of an accounting firm, and proposal to convene an extraordinary general meeting. The document is primarily about board decisions and meeting resolutions, not the full financial report itself. It does not contain detailed financial statements or comprehensive financial analysis. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-10-19 Chinese
关于补选独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an independent director to the company's board, including details about the resignation of a previous director and the qualifications of the new candidate. It does not contain financial data, audit information, or details about shareholder votes results. It specifically relates to changes in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a report or announcement of a report publication.
2022-10-19 Chinese
关于嘉事堂药业股份有限公司限售股份上市流通事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from two securities companies regarding the listing and circulation of restricted shares of a company after a non-public stock issuance. It discusses the approval by the China Securities Regulatory Commission, the number of shares issued, the date of listing, and the unlocking of restricted shares for circulation. The document is a formal verification and opinion letter by the sponsoring institutions confirming compliance with regulations and shareholder commitments. It does not contain financial statements or detailed financial data but is a regulatory compliance and verification report related to share circulation. This fits the category of Regulatory Filings (RNS) as it is a compliance document and verification opinion rather than a financial report or announcement of voting results or capital changes.
2022-09-27 Chinese
关于向特定对象发行股票的股份上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement regarding the lifting of restrictions on certain shares previously issued to a specific investor (China Everbright Group) and their subsequent listing and circulation on the Shenzhen Stock Exchange. It details the number of shares, the lock-up period, the shareholder involved, and the changes in share capital structure before and after the lifting of restrictions. The document also includes the verification opinion of the sponsoring institutions confirming compliance with relevant laws and regulations. There is no financial data, earnings information, or management discussion present. The document is not a full report but an announcement about share circulation and capital changes related to a specific share issuance event. This fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories.
2022-09-27 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as 嘉事堂药业股份有限公司2022年半年度报告全文, which translates to the full 2022 semi-annual report of the company. It contains detailed financial data, management discussion and analysis, company governance, environmental and social responsibility, and other comprehensive sections typical of an interim or quarterly report. The report period is clearly stated as January 1, 2022 to June 30, 2022, confirming it covers a half-year period. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-08-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.